| |
NAL Captive DDS Technologies |
|
Bio-D3 Site-Targeted DDS Technology |
| Bio-D3: Drug Delivery Design (D3) of Bioactive Drugs |
Injectable Drugs
Low water solubility
Organic solvent causing irritation |
|
Oral Drugs
Water-based formulation
Better safety
At-home therapy |
Liquid Drugs for
Dry Eye Syndrome
2 to 4 times per day |
|
Topical Drugs for
Dry Eye Syndrome
Once daily or every 3 days |
|
|
| Effects of Bio-D3 on the Stratum Corneum |
1. Soften the stratum corneum
2. Open up tight juncture temporarily and reversibly
3. Allow the active to quickly enter the skin layers
4. Promote effective and efficient absorption |
|
LatanylTM Fentanyl Patch (=Leading Fentanyl Patch) |
| The 72-hour LatanylTM 5-mg Fentanyl Patch is formulated in a reservoir |
| type transdermal delivery system essentially identical to the leading |
| commercial product. |
|
| |
|
| |
|
| |
 |
NAL 1236 |
| Leading Fentanyl Patch |
|
|
|
|
| Time(hr) |
|
| Release study medium = 250 ml pH 6.5 phosphate buffer |
| |
